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Summary
The role of the peroxisome proliferator-activated receptor- (PPAR) in the development of insulin-resistant diabetes was
evaluated using gain- and loss-of-function approaches. Transgenic mice overexpressing PPAR in muscle (MCK-PPAR
mice) developed glucose intolerance despite being protected from diet-induced obesity. Conversely, PPAR null mice
were protected from diet-induced insulin resistance in the context of obesity. In skeletal muscle, MCK-PPAR mice exhib-
ited increased fatty acid oxidation rates, diminished AMP-activated protein kinase activity, and reduced insulin-stimulated
glucose uptake without alterations in the phosphorylation status of key insulin-signaling proteins. These effects on mus-
cle glucose uptake involved transcriptional repression of the GLUT4 gene. Pharmacologic inhibition of fatty acid oxidation
or mitochondrial respiratory coupling prevented the effects of PPAR on GLUT4 expression and glucose homeostasis.
These results identify PPAR-driven alterations in muscle fatty acid oxidation and energetics as a potential link between
obesity and the development of glucose intolerance and insulin resistance.Introduction
We are witnessing the emergence of a pandemic of obesity,
metabolic syndrome, and type 2 diabetes mellitus (Engelgau
et al., 2004). Numerous studies have shown an intriguing link
between muscle lipid accumulation related to caloric excess
and the development of insulin resistance (Shulman, 2000).
However, the mechanisms linking altered muscle lipid metabo-
lism to the development of insulin resistance and type 2 diabe-
tes remain unclear. Recent evidence indicates that intracellular
lipid intermediates trigger cellular events that perturb insulin
signaling (Kim et al., 2001a; Griffin et al., 1999; Dresner et al.,
1999). Increased import and oxidation of fatty acids into insulin
target tissues such as skeletal muscle could also lead to recip-
rocal reductions in glucose utilization through events down-
stream or independent of the insulin-signaling pathway.
The peroxisome proliferator-activated receptor (PPAR α, β/δ,
and γ) family of lipid-activated nuclear receptors serves a criti-
cal role in the gene regulatory control of cellular lipid metabolic
pathways (Desvergne and Wahli, 1999). In skeletal muscle,
PPARα and PPARβ/δ are expressed at relatively abundant
levels and activate multiple cellular fatty acid uptake and utili-
zation pathways. Recent evidence points to a role for the
PPARα regulatory pathway in the lipid metabolic derangements
related to obesity and diabetes. However, the data linking the
PPARα pathway to the diabetic state have been conflicting.
Several synthetic ligands for PPAR family members, including
PPARγ and PPARα, have insulin-sensitizing effects in insulin-
resistant animal models (Guerre-Millo et al., 2000; Kim et al.,
2003). However, loss-of-function studies have shown that
PPARα null mice are resistant to high-fat diet- (Guerre-Millo et
al., 2001; Tordjman et al., 2001; Xu et al., 2004) and glucocorti-
coid-induced (Bernal-Mizrachi et al., 2003) insulin resistance.CELL METABOLISM : FEBRUARY 2005 · VOL. 1 · COPYRIGHT © 2005 ERecently, we found that the expression of PPARα and its
target genes is increased in the diabetic heart (Finck et al.,
2002). Transgenic mice with cardiac-specific overexpression of
PPARα (MHC-PPARα mice) exhibit increased fatty acid uptake
and oxidation and reciprocal inhibition of glucose uptake and
utilization (Finck et al., 2002). We sought to determine whether
chronic activation of the PPARα pathway leads to similar meta-
bolic derangements in other major insulin target tissues, thus
influencing the development of systemic insulin resistance and
glucose intolerance. To explore this possibility, PPARα gain-of-
function and loss-of-function studies were performed in mice.
We found that the activity of the skeletal muscle PPARα path-
way is directly linked to the development of insulin resistance,
glucose intolerance, and diabetes. Surprisingly, our results in-
dicate that an intact PPARα regulatory pathway is necessary
for the coupling of obesity and insulin resistance.
Results
The muscle PPAR gene regulatory pathway is activated
in obese, insulin-resistant UCP-DTA mice
We have shown previously that PPARα activity is increased in
the diabetic mouse heart (Finck et al., 2002). To determine
whether the PPARα gene regulatory pathway is activated in
major insulin target tissues of insulin-resistant mice, the ex-
pression of PPARα and several of its target genes was deline-
ated in skeletal muscle of obese, insulin-resistant UCP-DTA
mice prior to the onset of diabetes and compared to nontrans-
genic (NTG) littermate controls. UCP-DTA mice, a model of
metabolic syndrome, develop obesity, insulin resistance, and
diet-induced diabetes as a consequence of transgenic ablation
of nearly all brown adipose tissue (Lowell et al., 1993). TheLSEVIER INC. DOI 10.1016/j.cmet.2005.01.006 133
A R T I C L EFigure 1. Generation of mice with muscle-specific
activation of the PPARα regulatory pathway
A) Representative Northern blot analyses using RNA
from gastrocnemius from UCP-DTA or NTG mice
using the probes denoted at left. Graphs represent
mean (± standard error of the mean [SEM]) (n R 6
for each group) mRNA levels as determined by real-
time RT-PCR using RNA from gastrocnemius of
NTG and UCP-DTA mice. Values shown are cor-
rected for GAPDH signal intensity and normalized
(= 1.0) to the value of NTG mice. *p < 0.05 versus
NTG mice.
B) (Top) The schematic depicts the MCK-PPARα
construct used for transgene production and auto-
radiographs demonstrating relative PPARα trans-
gene mRNA (left) and protein (right) expression in
gastrocnemius muscle of nontransgenic (NTG) and
three lines of transgenic mice. PPARα transgene
mRNA expression in various tissues of MCK-PPARα
HE mice (bottom left). FLAG-PPARα protein levels
in gastrocnemius of LE and ME MCK-PPARα mice
compared to endogenous PPARα levels in liver and
soleus of NTG mice (bottom right).
C) Northern blot analyses performed using RNA iso-
lated from gastrocnemius of NTG or MCK-PPARα
(HE) mice and probes denoted at left are shown.
D) Mean (±SEM; n = 6) rates of palmitate oxidation
in epitrochlearis isolated from MCK-PPARα (HE) or
NTG littermate mice. *p < 0.05 versus NTG muscle.expression of the PPARα gene and its downstream target genes
encoding the mitochondrial fatty acid oxidation enzymes muscle
carnitine palmitoyltransferase (M-CPT I), very long-chain acyl-
CoA dehydrogenase (VLCAD), medium-chain acyl-CoA dehy-
drogenase (MCAD), and pyruvate dehydrogenase kinase 4
(PDK4), a potent inhibitor of glucose oxidation, was signifi-
cantly higher in skeletal muscle (Figure 1A) and heart (data not
shown) of UCP-DTA mice compared to NTG littermate con-
trols. Thus, activation of the muscle PPARα regulatory pathway
parallels the development of insulin resistance.
Muscle-specific overexpression of PPAR activates
cellular fatty acid metabolism and reciprocally
suppresses glucose uptake and utilization programs
The observation that PPARα target genes were activated in in-
sulin-resistant muscle led us to determine whether sustained134activation of PPARα in skeletal muscle is sufficient to cause
insulin resistance. To this end, transgenic mice with skeletal
muscle-specific overexpression of PPARα were generated
(MCK-PPARα mice). Three independent lines of MCK-PPARα
mice with low- (LE), medium- (ME), and high- (HE) level PPARα
overexpression were developed and characterized (Figure 1B).
The 1.9 kb MCK-PPARα transgene transcript was distin-
guished from the approximately 8 kb endogenous PPARα tran-
script in Northern blotting studies and was expressed in a mus-
cle-specific manner with highest expression in fast-twitch
muscle and lower expression in heart and soleus (Figure 1B).
As a reference for the magnitude of transgene expression, gas-
trocnemius PPARα protein levels in ME MCK-PPARα mice
were approximately double endogenous slow-twitch muscle
and heart PPARα content but were actually less than endoge-
nous PPARα levels found in liver (Figure 1B and data notCELL METABOLISM : FEBRUARY 2005
PPARα and obesity-related diabetesTable 1. Genes regulated in MCK-PPAR gastrocnemius muscle
Accession Gene name/symbol Fold change
Fatty acid uptake and binding proteins
BB534670 CD36/Cd36 5.4
AK017272 lipoprotein lipase/Lpl 4.4
NM_017399 fatty acid binding protein 1/Fabp1 5.4
NM_010174 fatty acid binding protein 3/Fabp3 3.3
BC002148 fatty acid binding protein 4/Fabp4 4.1
BC002008 fatty acid binding protein 5/Fabp5 2.7
Mitochondrial fatty acid oxidation
NM_009949 carnitine palmitoyltransferase 2/Cpt2 5.8
AV008091 mitochondrial acylcarnitine translocase/Slc25a20 3.7
NM_007383 short-chain acyl-CoA dehydrogenase/Acads 2.3
NM_007381 long-chain acyl-CoA dehydrogenase/Acadl 2.7
BC026559 very long-chain acyl-CoA dehydrogenase/Acadvl 2.7
AW107842 trifunctional protein, alpha subunit/Hadha 2.3
BG866501 trifunctional protein, beta subunit/Hadhb 2.4
AV018774 L-3-hydroxyacyl-Coenzyme A dehydrogenase/Hadhsc 5.6
NM_026172 2,4-dienoyl CoA reductase 1, mitochondrial/Decr1 5.2
Peroxisomal oxidation
NM_015729 acyl-CoA oxidase/Acox1 3.9
NM_016772 enoyl coenzyme A hydratase 1, peroxisomal/Ech1 3.5
AK009478 3, 2-enoyl-CoA isomerase, peroxisomal/Peci 2.4
BE952632 2,4 dienoyl-CoA reductase 2, peroxisomal/Decr2 3.3
Miscellaneous fatty acid metabolism
BI411560 monoglyceride lipase/Mgll 2.6
NM_019966 malonyl-CoA decarboxylase/Mlycd 2.3
NM_012006 cytosolic acyl-CoA thioesterase/Cte1 2.6
BC027063 3-hydroxybutyrate dehydrogenase/Bdh 2.0
BC024763 acetyl-Coenzyme A acetyltransferase 1/Acat1 2.3
BC007474 stearoyl-CoA desaturase 1/Scd1 5.5
BC003717 diglyceride acyltransferase 1/Dgat1 2.3
NM_026384 diglyceride acyltransferase 2/Dgat2 2.6
AI326423 sterol regulatory response element binding factor 1/Srebf1 3.0
BC012697 uncoupling protein 2/Ucp2 3.6
AF053352 uncoupling protein 3/Ucp3 2.6
Glucose and glycogen metabolism
NM_013743 pyruvate dehydrogenase kinase 4/Pdk4 5.9
BM207588 GLUT1/Slc2a1 0.33
NM_009204 GLUT4/Slc2a4 0.45
NM_008832 phosphorylase kinase α/Phka1 0.39
BM233125 phosphorylase kinase β/Phkb 0.29
J03293 phosphorylase kinase γ/Phkg 0.40
Insulin signaling
BB345784 insulin receptor substrate 1/Irs1 0.49
M60651 PI3 kinase regulatory subunit (p85α)/Pik3r1 3.6
Antioxidant genes
U38261 superoxide dismutase 3/Sod3 3.0
NM_009804 catalase/Cat 3.3
NM_011660 thioredoxin/Txn1 3.4
Values represent mean mRNA levels determined by microarray analyses using RNA from gastrocnemius of NTG and MCK-PPAR HE mice. The MCK-PPAR fold change
value is relative to the normalized (= 1.0) value of NTG signal.shown). MCK-PPARα mice were viable, bred normally, and
were anthropometrically similar to NTG littermate control mice
(data not shown).
To characterize the pattern of gene regulatory events elicited
by PPARα in the muscle of MCK-PPARα mice, transcriptional
profiling studies were performed with RNA isolated from gas-
trocnemius of 6-week-old male HE MCK-PPARα mice and
NTG littermate controls. As predicted, a broad program of
known PPARα target genes involved in cellular fatty acid im-
port, fatty acid binding, triglyceride synthesis, and mito-
chondrial and peroxisomal β-oxidation was activated in muscle
of MCK-PPARα mice (Table 1). The expression of genes en-
coding uncoupling proteins 2 and 3 was also upregulated.CELL METABOLISM : FEBRUARY 2005These results were validated in a representative subset of
target genes using Northern blotting analyses (Figure 1C) and
real-time RT-PCR (data not shown). We also detected in-
creased expression of genes encoding components of the TCA
cycle and multiple steps in the mitochondrial oxidative phos-
phorylation pathway (Figure 1C). As predicted by this gene ex-
pression profile, rates of palmitate oxidation were significantly
increased in skeletal muscle of transgenic mice compared to
NTG littermate controls (Figure 1D).
Notably, the gene expression array data also revealed a co-
ordinate downregulation of genes involved in cellular glucose
utilization pathways including import (GLUT4 and GLUT1) and
glycolysis (phosphofructokinase and glyceraldehyde-3-phos-135
A R T I C L Ephate dehydrogenase) in MCK-PPARα muscle (Figure 2A and
Table 1). In addition, expression of the gene encoding PDK4
was markedly increased in gastrocnemius of MCK-PPARα
mice versus NTG controls (Figure 2A). As predicted by the
gene expression profile, basal (HE) and insulin-stimulated (ME
and HE) 2-deoxyglucose (DG) uptake was significantly reduced
in isolated EDL muscle of MCK-PPARα ME and HE mice (Fig-
ure 2A).
To gain insight into the mechanism involved in the counter-
regulatory suppression of glucose utilization genes, PPARα
was constitutively overexpressed in rat L6 myoblasts using an
adenoviral vector (Ad-PPARα). Ad-PPARα markedly increased
expression of PDK4 and coordinately downregulated GLUT4
protein levels (Figure 2B). To determine whether the PPARα-
mediated effects occur at the level of transcription, cotransfec-Figure 2. Constitutive activation of the PPARα regu-
latory pathway in skeletal myocytes inhibits MEF2A-
dependent transcription of the GLUT4 gene
A) (Left) Northern blot analyses performed using
RNA isolated from gastrocnemius of NTG or MCK-
PPARα (HE) mice are shown. (Right) Mean basal
and insulin-stimulated uptake of 2-DG into EDL
muscle isolated from NTG or MCK-PPARα ME or
HE mice (nR 8). *p < 0.05 versus insulin-stimulated
NTG muscle. †p < 0.05 versus basal NTG muscle.
B) Western blotting studies performed with protein
extracts from L6 myotubes infected Ad-PPARα or
control adenovirus expressing green fluroscescent
protein (GFP). Blots were hybridized with antibodies
directed against proteins denoted at left.
C) Wild-type (GLUT4.Luc.779) and mutant (GLUT4.
Luc.MEFM) GLUT4 promoter reporter constructs
were cotransfected into L6 myoblasts with a PPARα
expression vector (pBOS-PPARα) or empty vector
control (pEFBOS). Bars represent mean (±SEM) lu-
ciferase activity in relative luciferase units (RLU) cor-
rected for β-galactosidase activity and normalized
to the value of empty expression vector-transfected
cells (= 100; n = 9). *p < 0.05 versus pEFBOS con-
trols.
D) L6 myoblasts were cotransfected with a heterol-
ogous reporter construct with multimerized MEF2
response elements (desMEF.LUC; schematic shown
at top) and pBOS-PPARα or pEF-BOS (n = 6). *p <
0.05 versus pEFBOS vector.
E) (Inset at top) Western blotting studies performed
with extracts from L6 myotubes infected with Ad-
PPARα and/or Ad-GFP (backbone control) using an-
tibodies denoted at left. Graph depicts mean levels
of MEF2A and PGC-1α mRNA in gastroc muscle
of 6-week-old HE MCK-PPARα or NTG littermate
control mice normalized to the value of NTG mice
(= 100; n = 7) as determined by real-time PCR. *p <
0.05 versus NTG mice.136tion studies were performed in L6 myoblasts using a PPARα
expression vector and a luciferase reporter driven by 779 bp
of the promoter region of the human GLUT4 gene promoter
region (GLUT4.Luc.779). GLUT4 promoter activity was signifi-
cantly repressed by PPARα (Figure 2C). The proximal GLUT4
promoter contains a critical myocyte enhancer factor 2 (MEF2)-
responsive element (RE) (Mora and Pessin, 2000). An inactiva-
ting mutation in the MEF2 RE reduced basal transcriptional
activity and completely abolished the PPARα-mediated down-
regulation of GLUT4 promoter activity. The activity of an inde-
pendent MEF2 reporter was also strikingly diminished by
PPARα (Figure 2D). Western blotting analyses revealed that
MEF2A protein levels were also reduced by PPARα overex-
pression in L6 myotubes (Figure 2E). Moreover, the expression
of both MEF2A and one of its coactivtors, PGC-1α (Michael etCELL METABOLISM : FEBRUARY 2005
PPARα and obesity-related diabetesal., 2001), was markedly diminished in HE MCK-PPARα muscle
compared to NTG controls (Figure 2E), as occurs in diabetic
muscle (Mora et al., 2001; Mootha et al., 2003). These results
suggest that PPARα-mediated repression of muscle glucose
utilization gene expression occurs at least in part via impair-
ment of MEF2A/PGC-1α-dependent control of GLUT4 gene
transcription.
Muscle-specific PPAR activation drives the development
of glucose intolerance and insulin resistance
in the context of a ‘lean’ phenotype
The observed muscle gene expression profile suggested that
glucose homeostasis might be perturbed in MCK-PPARα mice.
Accordingly, glucose tolerance and insulin sensitivity were ex-
amined in MCK-PPARα mice. We first noted that circulating
glucose and insulin levels were significantly increased in MCK-
PPARα HE mice compared to NTG littermate controls fed stan-
dard (STD) chow ad libitum or following an overnight fast (see
Table S1 in the Supplemental Data available with this article
online). Glucose tolerance testing (GTT) revealed that the blood
glucose excursion was significantly greater in both MCK-
PPARα HE and ME mice versus NTG controls (Figure 3A and
area-under-the-curve values shown in Table S2). ITT using 14-
week-old mice demonstrated that MCK-PPARα mice of both
ME and HE lines were resistant to the glucose-lowering effectsFigure 3. MCK-PPARα mice exhibit skeletal muscle glucose intolerance and in-
sulin resistance
A) Mean blood glucose levels in NTG, ME, or HE MCK-PPARα mice during GTT
(left) or ITT (right) studies (n R 10). *p < 0.05 versus NTG mice at the same
time point.
B) The results of hyperinsulinemic-euglycemic clamp studies with NTG and
MCK-PPARα HE mice. Bars represent mean rates of glucose appearance (Ra),
disappearance (Rd), and hepatic glucose production (End. Gluc. Prod.) deter-
mined under clamp conditions (n = 4). *p < 0.05 versus NTG mice.CELL METABOLISM : FEBRUARY 2005of an insulin bolus (Figure 3A and Table S2). Furthermore, hy-
perinsulinemic-euglycemic clamp studies confirmed that the
rate of peripheral glucose disposal was markedly diminished in
MCK-PPARα HE mice (Figure 3B). In contrast, hepatic glucose
production was not significantly different under clamped condi-
tions in MCK-PPARα mice. These results together with the ob-
servation of reduced insulin-stimulated 2-DG uptake in muscle
(Figure 2A) demonstrate that PPARα-driven derangements in
cellular fatty acid and glucose utilization are associated with a
muscle insulin-resistant phenotype.
To determine whether overexpression of PPARα in skeletal
muscle influences diet-induced obesity and insulin resistance,
NTG and HE MCK-PPARα mice were placed on high-fat (HF)
chow. Surprisingly, MCK-PPARα male and female mice gained
dramatically less weight on the HF chow (Figure 4A) despite
consuming similar quantities of food (data not shown). MCK-
PPARα mice had markedly smaller abdominal and subcutane-
ous fat depots compared to NTG controls (Figure 4B and 4C).
However, despite resistance to diet-induced obesity, MCK-
PPARα HE (Figure 4D and Table S2) and ME (Figure S1), mice
were more glucose intolerant as determined by GTT and insulin
resistant by ITT compared to NTG controls. The pale appear-
ance of the musculature of HF diet-fed MCK-PPARα HE mice
(Figure 4C) suggested muscle lipid accumulation. Indeed, Oil
Red O staining (data not shown) and quantitative determination
of triglyceride content (Figure 4E) confirmed that triglyceride-
rich lipid droplets accumulated within skeletal myocytes of HF-
fed but not STD chow-fed transgenic mice. These latter data
suggested that, despite increased oxidative capacity, fatty acid
uptake exceeds oxidation rates of transgenic muscle when
lipid is delivered to the muscle in high concentrations. These
results also demonstrate a striking uncoupling between HF
diet-induced obesity and the development of glucose intoler-
ance in the MCK-PPARα mice.
PPAR deficiency protects mice from HF diet-induced
skeletal muscle insulin resistance despite
the development of obesity
A loss-of-function strategy was used to further examine the
influence of PPARα on HF diet-induced perturbations in glu-
cose homeostasis. We first noted significantly greater weight
gain in PPARα null (PPARα−/−) versus PPARα+/+ mice after 4
weeks of HF diet (5.2 ± 0.30 g versus 4.1 ± 0.30 g; p < 0.05).
As expected, muscle palmitate oxidation rates in skeletal mus-
cle were lower in PPARα−/− mice compared to PPARα+/+ co-
horts (Figure 5A). Consistent with reduced fatty acid oxidative
capacity, gastrocnemius TAG levels were significantly higher in
HF-fed PPARα−/− mice (Figure 5B). However, despite greater
weight gain and higher levels of TAG in muscle of PPARα−/− mice,
glucose tolerance, insulin-stimulated glucose disposal (Figure
5C and Table S2), and 2-DG uptake (Figure 5D) were signifi-
cantly increased in skeletal muscle of PPARα−/− mice com-
pared to PPARα+/+ controls.
To further evaluate the contribution of the muscle PPARα
pathway to the development of insulin resistance caused by
HF diet, low-expressing (LE) MCK-PPARα mice were back-
crossed into a PPARα−/− background to generate PPARα null
mice with muscle-specific reconstitution of PPARα at physio-
logic levels (MCK-PPARα−/− mice). Glucose tolerance was not
affected by MCK-PPAR LE genotype in either PPARα−/− or
PPARα+/+ mice on STD chow (data not shown). However, fol-137
A R T I C L EFigure 4. Transgenic mice with muscle-specific ac-
tivation of PPARα gene regulatory pathways are
protected from diet-induced obesity but are insulin
resistant
A) Weight gain curves for male and female NTG and
HE MCK-PPARα mice receiving HF chow
(nR 11). *p < 0.05 versus MCK-PPARα mice of the
same sex.
B) Mean percent body fat as determined by DEXA
analyses using male NTG and HE MCK-PPARα
mice on STD chow or after 8 weeks on HF chow
(n R 6). *p < 0.05 versus all MCK-PPARα mice and
NTG mice on STD chow.
C) Representative ventral and dorsal images of nec-
ropsied NTG and HE MCK-PPARα mice after 8
weeks on HF chow are shown.
D) Blood glucose curves during GTT (left) and ITT
(right) using NTG and HE MCK-PPARα mice after 8
weeks on HF chow (n = 11). *p < 0.05 versus NTG
mice.
E) (Right) Mean TAG levels determined in gastrocne-
mius muscle obtained from standard chow or HF-
diet-fed NTG or HE MCK-PPARα mice (n = 6). *p <
0.05 versus STD-chow-fed mice. †p < 0.05 versus
NTG mice on HF chow.lowing a 4 week HF diet, MCK-PPARα−/− mice exhibited
greater glucose excursion compared to PPARα−/− mice during
GTT studies (Figure 5E and Table S2), yet PPARα−/− mice of
either MCK-PPARα genotype were significantly more glucose
tolerant compared to PPARα+/+ mice. Thus, reconstitution of
skeletal muscle PPARα to physiologic levels reduces the pro-
tective effect of PPARα−/− genotype against HF diet-induced
insulin resistance. However, the data indicate that other insulin
target tissues such as liver and adipose tissue are also affected
by the loss of PPARα.
Increased fatty acid oxidation and reduced AMPK
activity in muscle are linked to glucose intolerance
The observed glucose-intolerant phenotype of MCK-PPARα
mice could be due to the effects of myocyte lipid accumulation
on the insulin-signaling pathway. Surprisingly, insulin-stimu-
lated tyrosine phosphorylation of IRS-1 and Ser473 phosphor-
ylation state of Akt1/PKB in skeletal muscle of the MCK-
PPARα mice were not different from NTG controls (Figure 6A).138Moreover, IRS-1-associated PI3K activity following insulin
stimulation was also unaffected in MCK-PPARα mice (Figure
6A).
AMP-activated protein kinase (AMPK), an energy-sensing ki-
nase, has been shown to stimulate glucose uptake and utiliza-
tion independent of insulin signaling (Carling, 2004; Zhou et
al., 2001; Han et al., 2004). We found that AMPK activity was
markedly diminished in MCK-PPARα gastrocnemius versus lit-
termate NTG mice (Figure 6B). In addition, overexpression of
PPARα resulted in reduced levels of the serine 79-phosphory-
lated form of acetyl-CoA carboxylase (ACC), a known sub-
strate of AMPK. However, ACC phosphorylation was increased
by the AMPK activator AICAR, even in the presence of PPARα
(Figure 6C). Importantly, AICAR completely reversed the re-
pressive effect of PPARα on GLUT4 protein levels (Figure 6C).
In contrast to MCK-PPARα mice, AMPK activity was not dif-
ferent in muscle of high-fat-fed PPARα−/− and PPARα+/+ mice
(data not shown).
The observed reduction in muscle AMPK activity in MCK-CELL METABOLISM : FEBRUARY 2005
PPARα and obesity-related diabetesFigure 5. PPARα-driven derangements in mitochondrial FAO are critical for the
development of insulin resistance
A) Mean rates of palmitate oxidation in epitrochlearis and soleus isolated from
PPARα+/+ or PPARα−/− mice after 4 weeks on HF chow (n = 7). *P < 0.05 versus
the same PPARα+/+ muscle.
B) Mean levels of TAG in gastrocnemius from PPARα+/+ or PPARα−/− mice after
4 weeks on HF chow (n = 6). *p < 0.05 versus PPARα+/+ mice.
C) Blood glucose levels during GTT (left; n = 8) using PPARα+/+ or PPARα−/−
mice on STD chow or after 4 weeks on HF chow and ITT (right; n = 8) using mice
after 4 weeks on HF chow. *p < 0.05 versus all other groups.
D) Mean 2-DG uptake into isolated EDL muscle (n = 7) from PPARα+/+ and
PPARα−/− mice after 6 weeks on HF chow. *p < 0.05 versus non-insulin-treated
muscle. †p < 0.05 versus insulin-treated PPARα+/+ muscle.
E) The graphs depict the results of GTT with PPARα+/+, LE MCK-PPARα, or
PPARα−/−, or LE MCK-PPARα−/− mice on HF chow (n = 8). *p < 0.05 versus
PPARα−/− mice.PPARα mice led us to explore the possibility that alterations in
cellular energetics were involved in the glucose-intolerant phe-
notype. As an initial step, L6 myotubes were exposed to dini-
trophenol (DNP) to uncouple mitochondrial electron transport
from oxidative phosphorylation. DNP treatment completely re-
versed the repressive effects of PPARα on levels of Ser79-
phosphorylated ACC, GLUT4 expression, and MEF2A levels in
L6 myotubes (Figure 6C). We next explored the effects of inhib-
iting the PPARα-driven increase in mitochondrial fatty acid
oxidation on glucose tolerance in vivo. If increased rates ofCELL METABOLISM : FEBRUARY 2005β-oxidation are necessary for the glucose intolerance, inhibi-
tion of this pathway would ameliorate the phenotype. Specifi-
cally, PPARα-driven increases in fatty acid oxidation rates
could lead to a state of increased flux through mitochondrial
ATP-producing pathways, resulting in diminished AMPK-driven
muscle glucose uptake. Conversely, if accumulation of intracel-
lular lipid was directly related to the development of insulin re-
sistance, inhibition of fatty acid oxidation would worsen the
phenotype. Oxfenicine, an inhibitor of skeletal muscle mito-
chondrial fatty acid oxidation, was administered to UCP-DTA,
HE MCK-PPARα, and strain-matched littermate NTG control
mice for 4 days. As expected, inhibition of fatty acid oxidation
exacerbated lipid accumulation in skeletal myocytes (Figure
6D) but did not result in signs of illness or changes in feeding
habits (data not shown). Interestingly, despite profound muscle
lipid accumulation, inhibition of fatty acid oxidation improved
glucose tolerance in MCK-PPARα and UCP-DTA mice but not
controls (Figure 6D and Table S2). These results demonstrate
that increases in muscle fatty acid oxidation rates coupled to
mitochondrial oxidative phosphorylation are necessary for the
glucose-intolerant phenotype of UCP-DTA and MCK-PPARα
mice, an effect that is likely linked to AMPK activity and inde-
pendent or downstream of the insulin-signaling cascade.
Discussion
Herein we demonstrate that the expression of PPARα and its
target genes is increased in heart and skeletal muscle of obese
UCP-DTA mice. This finding is consistent with our previous ob-
servation that the PPARα pathway is activated in the hearts of
db/db and insulin-deficient mice (Finck et al., 2002) and other
work demonstrating that PPARα is activated in skeletal muscle
in diabetes (Yechoor et al., 2002; Jové et al., 2004; Patti et al.,
2003). PPARα regulates a broad array of genes involved in cel-
lular fatty acid uptake and oxidation in tissues that use fat for
ATP production, such as liver, heart, and skeletal muscle. The
control of this program by PPARα dictates tissue-specific en-
ergy substrate preferences under diverse physiologic condi-
tions. For example, short-term starvation markedly activates
PPARα in heart and liver to increase capacity for the oxidation
of fats to provide energy (Leone et al., 1999; Kersten et al.,
1999). It is not surprising, therefore, that the PPARα gene regu-
latory pathway is activated in heart and skeletal muscle in dia-
betic and starvation states, when capacity for ATP production
via glucose utilization pathways is constrained.
We found that chronic activation of PPARα in muscle leads
to reduced capacity for glucose uptake and insulin resistance.
Specifically, diet-induced insulin resistance was prevented in
a PPARα−/− background despite the development of obesity.
Conversely, overexpression of PPARα in muscle was sufficient
to cause glucose intolerance and insulin resistance in the
context of a “lean” phenotype. We also found that the mecha-
nism whereby chronic activation of PPARα reduces muscle
glucose uptake, glycolysis, and glucose oxidation occurs at
least in part at the level of gene expression. Activation of
PPARα repressed GLUT4 gene transcription, a key component
of the insulin-responsive glucose uptake pathway. PPARα-
mediated repression of the GLUT4 promoter requires a MEF2-
responsive element and was associated with diminished levels
of MEF2A and one of its coactivators, PGC-1α. Several lines
of evidence presented here indicate that the PPARα-mediated139
A R T I C L EFigure 6. Glucose intolerance in MCK-PPARα mice
is independent of impaired insulin signaling but is
associated with depressed AMPK activity and is de-
pendent on fatty acid oxidation and coupled respi-
ration
A) Representative immunoblots using protein were
isolated from gastrocnemius of saline- or insulin-
injected NTG or MCK-PPAR mice. Western blotting
analyses were performed using the antibodies listed
and IRS-1 immunoprecipitates (top) or whole-cell ly-
sates (bottom). The graph depicts mean IRS-1-
associated PI3K activity (arbitrary units (AU); n = 5)
determined using gastrocnemius protein IRS-1 im-
munoprecipitates collected from NTG and MCK-
PPARα HE mice 5 min after bolus insulin injection
(10 mU/g body weight).
B) Total AMPK activity in lysates from gastrocne-
mius of NTG and HE MCK-PPARα mice (n = 6).
*p < 0.05 versus NTG mice.
C) Western blotting studies using lysates from L6
myotubes infected with Ad-GFP or Ad-PPARα and
treated with AICAR (0.5 mM) (top), dinitrophenol
(DNP; 0.5 mM) (bottom), or appropriate vehicle con-
trol. Membranes were blotted with antibodies listed
at left.
D) Oil Red O-stained histologic images depicting
neutral lipid accumulation in gastrocnemius from
MCK-PPARα mice treated with vehicle or oxfeni-
cine. The graphs depict blood glucose levels during
GTT with NTG, HE MCK-PPARα (left graph), or
UCP-DTA (right graph) mice treated with vehicle or
oxfenicine (n R 6). *p < 0.05 versus mice of the
same genotype treated with vehicle.repression of GLUT4 transcription occurs through indirect
mechanisms related to cellular energy status. First, the activity
of the energy sensor kinase AMPK is reduced in the muscle
of MCK-PPARα mice. Conversely, activation of AMPK in L6
myotubes rescues the PPARα-mediated repression of GLUT4
expression. Second, uncoupling mitochondrial respiration from
oxidative phosphorylation, which is known to reduce ATP pro-
duction and increase AMPK activity, also rescues the effects
of PPARα on GLUT4 and MEF2A expression. Third, inhibition
of mitochondrial fatty acid oxidation, a major source of ATP
production in insulin-resistant muscle, improves glucose toler-
ance in MCK-PPARα and UCP-DTA mice. Collectively, these
results support the following conceptual model. Caloric excess
leads to redirection of fatty acids to skeletal muscle activating
the PPARα regulatory pathway. PPARα-driven increases in
mitochondrial FAO result in a cellular energy replete state, a140reduction in AMPK activity, and repression of MEF2A-depen-
dent transcription of the GLUT4 gene (and perhaps other glu-
cose utilization genes). Interestingly, AMPK activation has been
shown to increase the expression of MEF2A and PGC-1α in
skeletal muscle cells (Ojuka, 2004). However, given that we did
not find a difference in muscle AMPK activity in PPARα null
mice compared to wild-type mice, it is likely that mechanisms
in addition to alterations in AMPK are involved in the effects of
PPARα on muscle insulin responsivity.
Mounting evidence by others supports a role for altered
muscle lipid metabolism, specifically accumulation of fatty acid
intermediates, in the pathogenesis of insulin resistance. Lipid
intermediates such as acyl-CoA, ceramide, and other lipid moi-
eties have been implicated as mediators of derangements in
insulin signaling and diminished insulin-responsive transloca-
tion of GLUT4 to the plasma membrane (Shulman, 2000; SaltielCELL METABOLISM : FEBRUARY 2005
PPARα and obesity-related diabetesand Kahn, 2001). However, distinct mechanisms appear to be
responsible for impaired glucose tolerance in the MCK-PPARα
mice. We did not find significant decrements in insulin-stim-
ulated IRS-1 or Akt1 phosphorylation or PI3K activity in the
muscle of glucose-intolerant MCK-PPARα mice. Indeed, inhibi-
tion of fatty acid oxidation led to improved glucose tolerance
despite significant accumulation of intracellular neutral lipid.
These results indicate that the mechanism described here
occurs independent of lipid-mediated effects on the insulin-
signaling pathway. It is possible that alterations in the insulin-
signaling pathway occur at later stages of the diabetic state
coincident with alterations in mitochondrial function that could
further exacerbate intracellular lipid accumulation or alter the
specific cellular profile of lipid species. Alternatively, lipid accu-
mulation may serve as a signature of glucose intolerance and
insulin resistance, whereas fatty acid oxidation per se is the
important driver of the glucose intolerance.
A caveat should be raised regarding the direct applicability
of the observed PPARα-mediated downregulation of GLUT4
expression and obesity-related diabetes in humans. Most
studies of type 2 diabetes have not shown a downregulation
of muscle GLUT4 gene expression. However, little if any data
is available regarding GLUT4 expression in human diabetic
muscle prior to treatment. Given that we observed downregu-
lation of genes involved in the glycolytic and glucose oxidation
pathways, it is possible that regulatory points downstream of
GLUT4 are more relevant to the insulin-resistant and diabetic
state. It is also important to note that levels of MEF2A and
PGC-1α have been shown to be diminished in the muscle of
diabetics (Mootha et al., 2003; Mora et al., 2001; Patti et al.,
2003). Future studies of human tissue at multiple stages of in-
sulin resistance and diabetes will be informative.
The reciprocal inhibition of glucose metabolism by high-level
fatty acid utilization was first described in heart as the “glu-
cose-fatty acid cycle” by Randle and colleagues (Randle et al.,
1963). The Randle effect involves allosteric inhibition of glu-
cose oxidation enzymes by end products of fatty acid metabo-
lism. The mechanism described here also involves regulatory
“crosstalk” between fatty acid and glucose utilization path-
ways. From an energetic standpoint, this counterregulatory ef-
fect likely serves to prevent excessive flux of reducing equiva-
lents into final common energetic pathways such as the
tricarboxylic acid cycle or the electron transport chain. In addi-
tion, the reduction of glucose oxidation in the context of in-
creased fat oxidation spares energy substrate: a thrifty re-
sponse. However, several key differences between the Randle
effect and our results should be noted. In contrast to the
Randle effect, the mechanism described herein involves the
entire glucose utilization pathway including uptake, glycolysis,
and glucose oxidation. In addition, the Randle cycle affects
rapid changes in flux, whereas the PPARα-driven affects likely
mediate chronic changes in capacity. Although it has been ar-
gued that the Randle cycle cannot fully explain muscle insulin
resistance, our results extend the concept of fatty acid-glucose
counterregulation to chronic metabolic changes relevant to the
pathogenesis of obesity-related diabetes.
Recently, transgenic mice overexpressing PPARδ in skeletal
muscle were described (Wang et al., 2004). The phenotype of
the MCK-PPARα mice described here shares several features
with the PPARδ-overexpressing mouse. Specifically, both mod-
els exhibit enhanced expression of genes involved in fatty acidCELL METABOLISM : FEBRUARY 2005oxidation and mitochondrial respiration as well as resistance
to diet-induced obesity. However, in striking contrast, muscle-
specific overexpression of PPARδ led to improved insulin sen-
sitivity on HF chow, whereas MCK-PPARα mice are glucose
intolerant and insulin resistant. It is tempting to speculate that
these distinct phenotypic features reflect PPAR isoform-spe-
cific target gene expression profiles in skeletal muscle. Alterna-
tively, given that a VP-16 activation domain was added to the
PPARδ transgene cDNA (Wang et al., 2004), the observed dif-
ference could be due to a higher level of constitutive activity in
the muscle of the PPARδ transgene.
PPARγ and α modulators are used as pharmacologic therapy
for diabetes and dyslipidemias, respectively. Our results, impli-
cating the muscle PPARα pathway as a participant in the de-
velopment of insulin resistance, raises the question of whether
the chronic use of PPARα agonists in metabolic syndrome or
type II diabetes could lead to detrimental effects. The net ac-
tion of systemically administered PPAR modulators cannot be
determined by studies such as this one, which focus on a sin-
gle tissue. Moreover, genetic manipulations resulting in nuclear
receptor loss or gain of function cannot be equated with ad-
ministration of nuclear receptor ligand. However, our results do
suggest that inhibitors of specific muscle PPARα target path-
ways involved in fatty acid utilization could prove useful as
novel therapeutic targets. Indeed, oxfenicine and other inhibi-
tors of fatty acid oxidation were originally developed to treat
diabetes (Tutwiler et al., 1978; Mandarino et al., 1984; Barnett
et al., 1992; Collier et al., 1993). Furthermore, high-dose sali-
cylate, recently shown to improve insulin sensitivity on HF diet
(Kim et al., 2001b), can inhibit fatty acid oxidation in addition
to its antiinflammatory effects (Deschamps et al., 1991). Our
findings also provide further rationale for including the PPARα
gene regulatory complex pathway and its metabolic gene
targets as candidates in searches for genetic modifiers relevant
to metabolic syndrome and related disorders.
Experimental procedures
Animal studies
UCP-DTA transgenic mice (Lowell et al., 1993) in an FVB/N background
were obtained from Jackson Laboratories (Bar Harbor, ME). PPARα null
(PPARα−/−) mice were (Lee et al., 1995; Leone et al., 1999) purebred in the
C57BL6/J strain.
To constitutively activate PPARα in skeletal muscle, a cDNA encoding the
murine PPARα gene was cloned downstream of the mouse muscle creatine
kinase (MCK) gene promoter (kind gift of E.N. Olson, University of Texas
Southwestern). The MCK-PPARα construct was injected into one-cell F1
C57BL/6×CBA mouse embryos. Transgenic mice were identified by PCR
using primers specific for PPARα (AAGTTGCAGGAGGGGATTG) and the hu-
man growth hormone poly(A) component of the MCK construct (AGCTTG
GTTCCCGAATAGAC). MCK-PPARα mice were compared to littermate non-
transgenic (NTG) mice in all experiments. To generate PPARα−/− mice with
muscle-restricted reconstitution of PPARα, LE MCK-PPARα mice were
backcrossed six generations into the PPARα−/− background (C57BL6/J
strain).
To test the susceptibility to high-fat-diet-induced insulin resistance, mice
were administered a HF chow providing 43% of total calories from fat (Finck
et al., 2003). Oxfenicine (500 mg/kg; Sigma Chemical Co., St. Louis, MO)
was dissolved in DMSO, diluted in 0.25% methylcellulose, and adminis-
tered by daily oral gavage for 4 days. To examine insulin-stimulated insulin
signaling, mice were fasted overnight and injected intravenously with hu-
man insulin (10 mU/g body weight). Mice were killed 5 min later, and muscle
was dissected and snap frozen for protein isolation. All experimental proto-
cols were reviewed and approved by the Washington University Animal
Studies Committee.141
A R T I C L EGlucose and insulin tolerance testing
Studies were performed as described (Tordjman et al., 2001). Prior to
studies, mice were fasted overnight (GTT) or for 6 hr (ITT). In GTT studies,
mice were injected with a 10% solution of D-glucose (1 g/kg). Mice received
an intraperitoneal injection of human regular insulin (Eli Lilly and Co., India-
napolis, IN) at a dose of 0.75 U/kg body weight for ITT. Tail blood glucose
was determined at 0, 30, 60, and 120 min after challenge using a B-GLU-
COSE Analyzer (Hemacue AB, Angelholm, Sweden). Total area under the
curve (AUC) was calculated using the trapezoidal rule. For both GTT and
ITT, AUC was defined as the difference between baseline glucose levels
and the deflection caused by glucose or insulin challenge.
Hyperinsulinemic-euglycemic clamp studies
Clamp experiments were performed as described previously (Tordjman et
al., 2001) except that an insulin dose of 10 mU/kg/min was used.
Dual energy X-ray absorption studies
Dual energy X-ray absorption (DEXA) analyses were performed as de-
scribed (Bernal-Mizrachi et al., 2002) using a Lunar PIXIMUS DEXA system.
Studies employed 4-month-old male mice on standard or HF chow.
Measurement of glucose transport activity
Glucose transport activity was measured as described previously (Hansen
et al., 1998) using 2-deoxy-D-[1,2-3H] glucose. Palmitate oxidation rates in
isolated muscle preparations were determined using [9,10-3H] palmitate.
Northern and Western blotting analyses
Northern blotting analyses were performed as described (Kelly et al., 1989)
using radiolabeled cDNA probes. Western blotting studies were performed
with whole-cell lysates as previously described (Cresci et al., 1996) using
antibodies directed against PPARα (gift of J. Berger and J. Woods), GLUT4
(gift of M. Mueckler), pyruvate dehydrogenase kinase (PDK4; gift of R. Har-
ris), MEF2A (Santa Cruz Biotechnology), acetyl-CoA carboxylase (ACC)
phosphorylated at the serine 79 residue (Upstate Biotechnology), total
ACC2 (Alpha Diagnostic International), phospho-Akt1 (Ser473; Cell Signal-
ing Technology, Beverly, MA), Akt (pan-specific; Cell Signaling Technology),
and actin (Sigma Chemical Co., St. Louis, MO). An anti-IRS-1 antibody (gift
of M. Mueckler) was used to immunoprecipitate IRS-1 for subsequent im-
munoblotting with anti-phospho-tyrosine (Cell Signaling Technology) or
anti-IRS-1 antibodies and for PI3K assays.
Quantitative real-time RT-PCR analyses
First-strand cDNA was generated by reverse transcription using total RNA.
Real-time RT-PCR was performed using the ABI PRISM 7700 sequence
detection system (Applied Biosystems, Foster City, CA) and the TAQMAN
kit. FAM-labeled probes and corresponding primer sets (shown in Table S3)
were designed to span exon splice borders. Arbitrary units of target mRNA
were corrected by measuring the levels of GAPDH mRNA in the same PCR
reaction with a VIC-labeled probe (Applied Biosystems).
Gene expression array studies
Total RNA isolated from gastrocnemius muscle of 6-week-old littermate
NTG and MCK-PPARα HE mice was used in microarray studies performed
as previously described (Huss et al., 2004). The Alvin Siteman Cancer Cen-
ter’s Multiplexed Gene Analysis Core at Washington University School of
Medicine performed hybridization to Affymetrix mouse MOE430A chips.
Signal intensity ratios were calculated at MCK-PPAR/NTG in order to detect
changes due to PPARα activation.
Determination of AMPK and PI3K activity
Total AMPK activity was determined as described (Sambandam et al., 2004)
using gastrocnemius from NTG or MCK-PPARα HE mice. IRS-1-associated
PI3K activity was determined as described (Backer et al., 1992) following
IRS-1 immunoprecipitation.
Plasma chemistry and tissue TAG content
Plasma TAG, free fatty acids, and cholesterol levels were determined using
colorimetric assays. Muscle TAG was extracted using chloroform and quan-
tified using a colorimetric assay.142Histologic analyses
After harvest, white vastus was snap frozen in OCT compound in a cryo-
mold for sectioning. To detect neutral lipid, the sections were stained with
Oil Red O and counterstained with hematoxylin.
Additional Experimental Procedures regarding cell culture-based studies
can be found in the Supplemental Data.
Supplemental data
Supplemental Data include one figure, three tables, Supplemental Experi-
mental Procedures, and Supplemental References and can be found with
this article online at http://www.cellmetabolism.org/cgi/content/full/1/2/133/
DC1/.
Acknowledgments
The authors wish to thank Mary Wingate for her excellent assistance in
manuscript preparation and the Digestive Diseases Research Core Center
(P30 DK52574) at Washington University for assistance with tissue histol-
ogy. Special thanks to Frank Gonzalez and Jeff Peters for providing the
PPARα null mice and Rich Hresko and Michael Mueckler for technical assis-
tance with PI3 kinase assays. B.N.F. is supported by an NIDDK K01 award
(KO1 DK062903). This work was also supported by NIH grants RO1
DK45416, RO1 HL58427, P30 DK56341, P60 DK20579, PO1 HL5727805,
PO1-HL13851, and JDFI 996003.
Received: September 17, 2004
Revised: December 8, 2004
Accepted: January 24, 2005
Published: February 15, 2004
References
Backer, J.M., Schroeder, G.G., Kahn, C.R., Myers, M.G., Jr., Wilden, P.A.,
Cahill, D.A., and White, M.F. (1992). Insulin stimulation of phosphatidylinosi-
tol 3-kinase activity maps to insulin receptor regions required for endoge-
nous substrate phosphorylation. J. Biol. Chem. 267, 1367–1374.
Barnett, M., Collier, G.R., and O’Dea, K. (1992). The longitudinal effect of
inhibiting fatty acid oxidation in diabetic rats fed a high fat diet. Horm.
Metab. Res. 24, 360–362.
Bernal-Mizrachi, C., Weng, S., Li, B., Nolte, L.A., Feng, C., Coleman, T.,
Holloszy, J.O., and Semenkovich, C.F. (2002). Respiratory uncoupling
lowers blood pressure through a leptin-dependent mechanism in genetically
obese mice. Arterioscler. Thromb. Vasc. Biol. 22, 961–968.
Bernal-Mizrachi, C., Weng, S., Feng, C., Finck, B.N., Knutsen, R.H., Leone,
T.C., Coleman, T., Mecham, R.P., Kelly, D.P., and Semenkovich, C.F. (2003).
Dexamethasone induction of hypertension and diabetes is PPAR-α depen-
dent in LDL receptor-null mice. Nat. Med. 9, 1069–1075.
Carling, D. (2004). The AMP-activated protein kinase cascade-a unifying
system for energy control. Trends Biochem. Sci. 29, 18–24.
Collier, G.R., Traianedes, K., Macaulay, S.L., and O’Dea, K. (1993). Effect of
fatty acid oxidation inhibition on glucose metabolism in diabetic rats. Horm.
Metab. Res. 25, 9–12.
Cresci, S., Wright, L.D., Spratt, J.A., Briggs, F.N., and Kelly, D.P. (1996).
Activation of a novel metabolic gene regulatory pathway by chronic stimula-
tion of skeletal muscle. Am. J. Physiol. 270, C1413–C1420.
Deschamps, D., Fisch, C., Fromenty, B., Berson, A., Degott, C., and Pes-
sayre, D. (1991). Inhibition by salicylic acid of the activation and thus oxida-
tion of long chain fatty acids. Possible role in the development of Reye’s
syndrome. J. Pharmacol. Exp. Ther. 259, 894–904.
Desvergne, B., and Wahli, W. (1999). Peroxisome proliferator-activated re-
ceptors: Nuclear control of metabolism. Endocr. Rev. 20, 649–688.
Dresner, A., Laurent, D., Marcucci, M., Griffin, M.E., Dufour, S., Cline, G.W.,
Slezak, L.A., Andersen, D.K., Hundal, R.S., Rothman, D.L., et al. (1999).CELL METABOLISM : FEBRUARY 2005
PPARα and obesity-related diabetesEffects of free fatty acids on glucose transport and IRS-1-associated phos-
phatidylinositol 3-kinase activity. J. Clin. Invest. 103, 253–259.
Engelgau, M.M., Geiss, L.S., Saaddine, J.B., Boyle, J.P., Benjamin, S.M.,
Gregg, E.W., Tierney, E.F., Rios-Burrows, N., Mokdad, A.H., Ford, E.S., et
al. (2004). The evolving diabetes burden in the United States. Ann. Intern.
Med. 140, 945–950.
Finck, B., Lehman, J.J., Leone, T.C., Welch, M.J., Bennett, M.J., Kovacs,
A., Han, X., Gross, R.W., Kozak, R., Lopaschuk, G.D., and Kelly, D.P. (2002).
The cardiac phenotype induced by PPARα overexpression mimics that
caused by diabetes mellitus. J. Clin. Invest. 109, 121–130.
Finck, B., Han, X., Courtois, M., Aimond, F., Nerbonne, J.M., Kovacs, A.,
Gross, R.W., and Kelly, D.P. (2003). A critical role for PPAR α-mediated lipo-
toxicity in the pathogenesis of diabetic cardiomyopathy: modulation of phe-
notype by dietary fat content. Proc. Natl. Acad. Sci. USA 100, 1226–1231.
Griffin, M.E., Marcucci, M.J., Cline, G.W., Bell, K., Barucci, N., Lee, D.,
Goodyear, L.J., Kraegen, E.W., White, M.F., and Shulman, G.I. (1999). Free
fatty acid-induced insulin resistance is associated with activity of protein
kinase C theta and alterations in the insulin signaling cascade. Diabetes 48,
1270–1274.
Guerre-Millo, M., Gervois, P., Raspe, E., Madsen, L., Poulain, P., Derudas,
B., Herbert, J.M., Winegar, D.A., Willson, T.M., Fruchart, J.C., et al. (2000).
Peroxisome proliferator-activated receptor alpha activators improve insulin
sensitivity and reduce adiposity. J. Biol. Chem. 275, 16638–16642.
Guerre-Millo, M., Rouault, C., Poulain, P., Andre, J., Poitout, V., Peters, J.M.,
Gonzalez, F.J., Fruchart, J.C., Reach, G., and Staels, B. (2001). PPAR-alpha-
null mice are protected from high-fat diet-induced insulin resistance. Diabe-
tes 50, 2809–2814.
Han, D.H., Nolte, L.A., Ju, J.S., Coleman, T., Holloszy, J.O., and Semenko-
vich, C.F. (2004). UCP-mediated energy depletion in skeletal muscle in-
creases glucose transport despite lipid accumulation and mitochondrial
dysfunction. Am. J. Physiol. Endocrinol. Metab. 286, E347–E353.
Hansen, P.A., Wang, W., Marshall, B.A., Holloszy, J.O., and Mueckler, M.
(1998). Dissociation of GLUT4 translocation and insulin-stimulated glucose
transport in transgenic mice overexpressing GLUT1 in skeletal muscle. J.
Biol. Chem. 273, 18173–18179.
Huss, J.M., Pinéda Torra, I., Staels, B., Giguère, V., and Kelly, D.P. (2004).
ERRα directs PPARα signaling in the transcriptional control of energy me-
tabolism in cardiac and skeletal muscle. Mol. Cell. Biol. 24, 9079–9091.
Jové, M., Salla, J., Planavila, A., Cabrero, À., Michalik, L., Wahli, W., Laguna,
J.C., and Vázquez-Carrera, M. (2004). Impaired expression of NADH dehy-
drogenase subunit 1 and PPARγ coactivator-1 in skeletal muscle of ZDF
rats: restoration by troglitazone. J. Lipid Res. 45, 113–123.
Kelly, D.P., Gordon, J.I., Alpers, R., and Strauss, A.W. (1989). The tissue-
specific expression and developmental regulation of the two nuclear genes
encoding rat mitochondrial proteins: medium-chain acyl-CoA dehydroge-
nase and mitochondrial malate dehydrogenase. J. Biol. Chem. 264,
18921–18925.
Kersten, S., Seydoux, J., Peters, J.M., Gonzalez, F.J., Desvergne, B., and
Wahli, W. (1999). Peroxisome proliferator-activated receptor α mediates the
adaptive response to fasting. J. Clin. Invest. 103, 1489–1498.
Kim, J.K., Fillmore, J.J., Chen, Y., Yu, C., Moore, I.K., Pypaert, M., Lutz,
E.P., Kako, Y., Velez-Carrasco, W., Goldberg, I.J., et al. (2001a). Tissue-
specific overexpression of lipoprotein lipase causes tissue-specific insulin
resistance. Proc. Natl. Acad. Sci. USA 98, 7522–7527.
Kim, J.K., Kim, Y.J., Fillmore, J.J., Chen, Y., Moore, I., Lee, J., Yuan, M., Li,
Z.W., Karin, M., Perret, P., et al. (2001b). Prevention of fat-induced insulin
resistance by salicylate. J. Clin. Invest. 108, 437–446.
Kim, H., Haluzik, M., Asghar, Z., Yau, D., Joseph, J.W., Fernandez, A.M.,
Reitman, M.L., Yakar, S., Stannard, B., Heron-Milhavet, L., et al. (2003).
Peroxisome proliferator-activated receptor-α agonist treatment in a trans-
genic model of type 2 diabetes reverses the lipotoxic state and improves
glucose homeostasis. Diabetes 52, 1770–1778.CELL METABOLISM : FEBRUARY 2005Lee, S.S.T., Pineau, T., Drago, J., Lee, E.J., Owens, J.W., Kroetz, D.L., Fer-
nandez-Salguero, P.M., Westphal, H., and Gonzalez, F.J. (1995). Targeted
disruption of the α isoform of the peroxisome proliferator-activated receptor
gene in mice results in abolishment of the pleiotropic effects of peroxisome
proliferators. Mol. Cell. Biol. 15, 3012–3022.
Leone, T.C., Weinheimer, C.J., and Kelly, D.P. (1999). A critical role for the
peroxisome proliferator-activated receptor alpha (PPARα) in the cellular
fasting response: The PPARα -null mouse as a model of fatty acid oxidation
disorders. Proc. Natl. Acad. Sci. USA 96, 7473–7478.
Lowell, B.B., Susulic, V., Hamann, A., Lawitts, J.A., Himms-Hagen, J.,
Boyer, B.B., Kozak, L.P., and Flier, J.S. (1993). Development of obesity in
transgenic mice after genetic ablation of brown adipose tissue. Nature 366,
740–742.
Mandarino, L., Tsalikian, E., Bartold, S., Marsh, H., Carney, A., Buerklin, E.,
Tutwiler, G., Haymond, M., Handwerger, B., and Rizza, R. (1984). Mecha-
nism of hyperglycemia and response to treatment with an inhibitor of fatty
acid oxidation in a patient with insulin resistance due to antiinsulin receptor
antibodies. J. Clin. Endocrinol. Metab. 59, 658–664.
Michael, L.F., Wu, Z., Cheatham, R.B., Puigserver, P., Adelmant, G., Leh-
man, J.J., Kelly, D.P., and Spiegelman, B.M. (2001). Restoration of insulin-
sensitive glucose transporter (GLUT4) gene expression in muscle cells by
the transcriptional coactivator PGC-1. Proc. Natl. Acad. Sci. USA 98,
3820–3825.
Mootha, V.K., Lindgren, C.M., Eriksson, K.-F., Subramanian, A., Sihag, S.,
Lehar, J., Puigserver, P., Carlsson, E., Ridderstrale, M., Laurila, E., et al.
(2003). PGC-1α-responsive genes involved in oxidative phosphorylation are
coordinately downregulated in human diabetes. Nat. Genet. 34, 267–273.
Mora, S., and Pessin, J.E. (2000). The MEF2A isoform is required for striated
muscle-specific expression of the insulin-responsive GLUT4 glucose trans-
porter. J. Biol. Chem. 275, 16323–16328.
Mora, S., Yang, C., Ryder, J.W., Boeglin, D., and Pessin, J.E. (2001). The
MEF2A and MEF2D isoforms are differentially regulated in muscle and adi-
pose tissue during states of insulin deficiency. Endocrinology 142, 1999–
2004.
Ojuka, E.O. (2004). Role of calcium and AMP kinase in the regulation of
mitochondrial biogenesis and GLUT4 levels in muscle. Proc. Nutr. Soc. 63,
275–278.
Patti, M.E., Butte, A.J., Crunkhorn, S., Cusi, K., Berria, R., Kashyap, S.,
Miyazaki, Y., Kohane, I., Costello, M., Saccone, R., et al. (2003). Coordi-
nated reduction of genes of oxidative metabolism in humans with insulin
resistance and diabetes: potential role of PGC1 and NRF1. Proc. Natl. Acad.
Sci. USA 100, 8466–8471.
Randle, P.J., Hales, C.N., and Garland, P.B. (1963). The glucose fatty-acid
cycle. Its role in insulin sensitivity and the metabolic disturbances of diabe-
tes mellitus. Lancet 1, 785–789.
Saltiel, A.R., and Kahn, C.R. (2001). Insulin signalling and the regulation of
glucose and lipid metabolism. Nature 414, 799–806.
Sambandam, N., Steinmetz, M., Chu, A., Altarejos, J.Y., Dyck, J.R., and
Lopaschuk, G.D. (2004). Malonyl-CoA decarboxylase (MCD) is differentially
regulated in subcellular compartments by 5# AMP-activated protein kinase
(AMPK). Studies using H9c2 cells overexpressing MCD and AMPK by ade-
noviral gene trasfer technique. Eur. J. Biochem. 271, 2831–2840.
Shulman, G.I. (2000). Cellular mechanisms of insulin resistance. J. Clin. In-
vest. 106, 171–176.
Tordjman, K., Bernal-Mizrachi, C., Zemany, L., Weng, S., Feng, C., Zhang,
F., Leone, T.C., Coleman, T., Kelly, D.P., and Semenkovich, C.F. (2001). Per-
oxisome proliferator-activated receptor α deficiency reduces insulin resis-
tance and atherosclerosis in apoE-null mice. J. Clin. Invest. 107, 1025–
1034.
Tutwiler, G.F., Kirsch, T., Mohrbacher, R.J., and Ho, W. (1978). Pharmaco-143
A R T I C L Elogic profile of methyl 2-tetradecylglycidate (McN-3716)—an orally effective
hypoglycemic agent. Metabolism 10, 1539–1556.
Wang, Y.-X., Zhang, C.L., Yu, R.T., Cho, H.K., Nelson, M.C., Bayuga-
Ocampo, C.R., Ham, J., Kang, H., and Evans, R.M. (2004). Regulation of
muscle fiber type and running endurance by PPARdelta. PLoS Biol. 2, e294.
DOI: 10.1371/journal.pbio.0020294
Xu, J., Chang, V., Joseph, S.B., Trujillo, C., Bassilian, S., Saad, M.F., Lee,
W.N., and Kurland, I.J. (2004). Peroxisomal proliferator-activated receptor144alpha deficiency diminishes insulin-responsiveness of gluconeogenic/gly-
colytic/pentose gene expression and substrate cycle flux. Endocrinology
145, 1087–1095.
Yechoor, V.K., Patti, M.E., Saccone, R., and Kahn, C.R. (2002). Coordinated
patterns of gene expression for substrate and energy metabolism in skeletal
muscle of diabetic mice. Proc. Natl. Acad. Sci. USA 99, 10587–10592.
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M.,
Ventre, J., Doebber, T., Fujii, N., et al. (2001). Role of AMP-activated protein
kinase in mechanism of metformin action. J. Clin. Invest. 108, 1167–1174.CELL METABOLISM : FEBRUARY 2005
